A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 26, 2018

Primary Completion Date

July 11, 2018

Study Completion Date

July 11, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

Alogliptin

Alogliptin tablets.

DRUG

Pioglitazone

Pioglitazone tablets.

DRUG

SYR-322-4833 BL

SYR-322-4833 BL FDC tablets.

Trial Locations (1)

Non-governmental healthcare Institution Road Clinical Hospital at the station Yaroslavl JSC Russian Railways, Yaroslavl